

21 Mar 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai hands Aduhelm to Biogen; and *Scrip Asks* what 2022 holds for digital and telehealth.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 18 March 2022, including: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; [\*Eisai Co., Ltd.\*](#) hands Aduhelm to [\*Biogen, Inc.\*](#); and *Scrip Asks* what 2022 holds for digital and telehealth.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*Nektar/BMS's IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders\*](#)" - *Scrip*, 14 Mar, 2022.)

(Also see "[\*Rare Setback For Merck & Co And AstraZeneca's Keytruda-Lynparza Combo In Prostate Cancer\*](#)" - *Scrip*, 16 Mar, 2022.)

(Also see "[\*Financial Decoupling: China Biotechs Brace For Potential US Delistings, Softening Economy\*](#)" - *Scrip*, 16 Mar, 2022.)

(Also see "[\*Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement\*](#)" - *Scrip*, 14

Mar, 2022.)

(Also see "[\*Scrip Asks...What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth\*](#)" - Scrip, 16 Mar, 2022.)

[Click here to explore this interactive content online](#) ✨